Article
Oncology
Motoo Nagane, Koichi Ichimura, Ritsuko Onuki, Daichi Narushima, Mai Honda-Kitahara, Kaishi Satomi, Arata Tomiyama, Yasuhito Arai, Tatsuhiro Shibata, Yoshitaka Narita, Takeo Uzuka, Hideo Nakamura, Mitsutoshi Nakada, Yoshiki Arakawa, Takanori Ohnishi, Akitake Mukasa, Shota Tanaka, Toshihiko Wakabayashi, Tomokazu Aoki, Shigeki Aoki, Soichiro Shibui, Masao Matsutani, Keisuke Ishizawa, Hideaki Yokoo, Hiroyoshi Suzuki, Satoshi Morita, Mamoru Kato, Ryo Nishikawa
Summary: This study evaluated the efficacy and safety of bevacizumab in Japanese patients with newly diagnosed glioblastoma and identified an expression classifier that may predict patient prognosis.
Article
Multidisciplinary Sciences
Loig Vaugier, Loic Ah-Thiane, Maud Aumont, Emmanuel Jouglar, Mario Campone, Camille Colliard, Ludovic Doucet, Jean-Sebastien Frenel, Carole Gourmelon, Marie Robert, Stephane-Andre Martin, Tanguy Riem, Vincent Roualdes, Loic Campion, Augustin Mervoyer
Summary: The study reviewed elderly patients with GBM referred for 6-week CRT, finding that CRT treatment was feasible for this population, even in the case of post-operative neurological disabilities. Age and neurological disabilities did not necessarily affect patient outcomes.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Carlen A. Yuen, Marissa Barbaro, Aya Haggiagi
Summary: Management of elderly patients with newly diagnosed glioblastoma (eGBM) presents unique challenges. Although progress has been made in defining the optimal therapeutic approach for these patients, many questions remain unanswered.
CURRENT ONCOLOGY REPORTS
(2022)
Article
Oncology
K. Ina Ly, Leland G. Richardson, Mofei Liu, Alona Muzikansky, Jonathan Cardona, Kevin Lou, Andrew L. Beers, Ken Chang, James M. Brown, Xiaoyue Ma, David A. Reardon, Isabel C. Arrillaga-Romany, Deborah A. Forst, Justin T. Jordan, Eudocia Q. Lee, Jorg Dietrich, Lakshmi Nayak, Patrick Y. Wen, Ugonma Chukwueke, Anita Giobbie-Hurder, Bryan D. Choi, Tracy T. Batchelor, Jayashree Kalpathy-Cramer, William T. Curry, Elizabeth R. Gerstner
Summary: The efficacy of Bavituximab, a monoclonal antibody with anti-angiogenic and immunomodulatory properties, was evaluated in newly diagnosed patients with glioblastoma (GBM) who also received radiotherapy and temozolomide. The study showed that Bavituximab has activity in the treatment of newly diagnosed GBM and resulted in on-target depletion of intratumoral immunosuppressive MDSCs. Elevated pre-treatment expression of myeloid-related transcripts in GBM may predict response to Bavituximab.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Emilie Le Rhun, Felix Boakye Oppong, Maureen Vanlancker, Roger Stupp, Burt Nabors, Olivier Chinot, Wolfgang Wick, Matthias Preusser, Thierry Gorlia, Michael Weller
Summary: Myelosuppression during temozolomide chemoradiotherapy is associated with the survival of patients with newly diagnosed glioblastoma. Female patients experience more marrow toxicity than males. Lymphopenia is related to the overall survival of patients.
Review
Oncology
Bryan Oronsky, Tony R. Reid, Arnold Oronsky, Navjot Sandhu, Susan J. Knox
Summary: Glioblastoma is an aggressive primary intra-axial brain tumor with poor prognosis, and current treatment involves surgery, radiotherapy, and chemotherapy. This review summarizes the characteristics, current treatment options, and potential future therapeutic prospects for the disease.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Maciej Harat, Maciej Blok, Izabela Miechowicz, Izabela Wiatrowska, Karolina Makarewicz, Bogdan Malkowski
Summary: This study evaluated the safety and efficacy of simultaneous integrated boost (SIB) planned using dual FET-PET for postoperative GBM treatment. The results showed that SIB with dual FET-PET improved survival outcomes, but there was a risk of radiation necrosis.
CLINICAL CANCER RESEARCH
(2022)
Article
Cell Biology
Inge Compter, Danielle B. P. Eekers, Ann Hoeben, Kasper M. A. Rouschop, Bart Reymen, Linda Ackermans, Jan Beckervordersantforth, Noel J. C. Bauer, Monique M. Anten, Pieter Wesseling, Alida A. Postma, Dirk De Ruysscher, Philippe Lambin
Summary: Treatment with chloroquine in combination with radiotherapy and concurrent temozolomide for newly diagnosed glioblastoma showed favorable toxicity and promising overall survival. The maximum tolerated dose was determined to be 200 mg of chloroquine daily. Further clinical studies are supported by these results.
Review
Multidisciplinary Sciences
Suely Maymone de Melo, Gustavo Nader Marta, Carolina de Oliveira Cruz Latorraca, Camila Bertini Martins, Orestis Efthimiou, Rachel Riera
Summary: This review found no evidence of a difference between the evaluated HRTs for efficacy and safety.
Article
Medicine, General & Internal
Nalee Kim, Do Hoon Lim, Jung Won Choi, Jung-Il Lee, Doo-Sik Kong, Do-Hyun Nam, Ho Jun Seol
Summary: The study aimed to investigate the outcomes of hypofractionated radiotherapy (HypoRT) in patients with glioblastoma (GBM) receiving concurrent temozolomide. The results showed that HypoRT had comparable progression-free survival and overall survival to conventionally fractionated radiotherapy (ConvRT), and significantly reduced the occurrence of lymphopenia.
YONSEI MEDICAL JOURNAL
(2023)
Article
Oncology
Jie Chen, Tingting Wang, Wanming Liu, Hui Qiu, Nie Zhang, Xueting Chen, Xin Ding, Longzhen Zhang
Summary: This study suggests that extended adjuvant temozolomide treatment can significantly improve the prognosis of newly diagnosed glioblastoma patients, regardless of p53 mutation status. The effect of this treatment also varies among patients with different MGMT methylation, IDH1 mutation, and Ki67 expression levels.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Gilbert Youssef, Rifaquat Rahman, Camden Bay, Wei Wang, Mary Jane Lim-Fat, Omar Arnaout, Wenya Linda Bi, Daniel N. Cagney, Yuh-Shin Chang, Timothy F. Cloughesy, Matthew DeSalvo, Benjamin M. Ellingson, Thomas F. Flood, Elizabeth R. Gerstner, L. Nicolas Gonzalez Castro, Jeffrey P. Guenette, Albert E. Kim, Eudocia Q. Lee, Jose R. McFaline-Figueroa, Christopher A. Potter, David A. Reardon, Raymond Y. Huang, Patrick Y. Wen
Summary: This study compared the performance of RANO criteria with modified RANO (mRANO) and immunotherapy RANO (iRANO) criteria in patients with newly diagnosed glioblastoma and recurrent GBM. The results showed similar correlations between PFS and OS for RANO and mRANO. Confirmation scans within 12 weeks after radiotherapy improved correlations in nGBM. Using postradiation MRI as the baseline scan had better correlation in nGBM compared to using pre-radiation MRI. Evaluation of FLAIR sequences did not improve the correlation. iRANO criteria did not provide significant benefit in patients receiving immune checkpoint inhibitors.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Ian Y. Lee, Simon Hanft, Michael Schulder, Kevin D. Judy, Eric T. Wong, J. Bradley Elder, Linton T. Evans, Mario Zuccarello, Julian Wu, Sonikpreet Aulakh, Vijay Agarwal, Rohan Ramakrishna, Brian J. Gill, Alfredo Quinones-Hinojosa, Cameron Brennan, Brad E. Zacharia, Carlos Eduardo Silva Correia, Madhavi Diwanji, Gregory K. Pennock, Charles Scott, Raul Perez-Olle, David W. Andrews, John A. Boockvar
Summary: This article describes the design and rationale of a randomized, double-blind, phase IIb trial evaluating the efficacy of IGV-001 compared with placebo in patients with ndGBM, followed by standard-of-care treatment. The therapy aims to induce tumor-specific immune response in ndGBM patients.
Article
Oncology
Muayad F. Almahariq, Thomas J. Quinn, Jessica D. Arden, P. T. Roskos, George D. Wilson, Brian Marples, Inga S. Grills, Peter Y. Chen, Daniel J. Krauss, Prakash Chinnaiyan, Joshua T. Dilworth
Summary: This study investigated the use of pulsed radiation therapy (PRT) in the treatment of patients with newly diagnosed glioblastoma (GBM). The results showed that PRT treatment is feasible, effective, and can maintain neurocognitive function and quality of life in patients with GBM. Further validation in larger prospective trials is warranted.
Article
Oncology
J. Biau, E. Thivat, E. Chautard, D. Stefan, M. Boone, B. Chauffert, C. Bourgne, D. Richard, I Molnar, S. Levesque, R. Bellini, F. Kwiatkowski, L. Karayan-Tapon, P. Verrelle, C. Godfraind, X. Durando
Summary: This phase 1 trial aimed to determine the maximum tolerated dose of a p38-MAPK inhibitor, ralimetinib, in combination with radiotherapy and chemotherapy for newly diagnosed GBM patients. The study found that the MTD of ralimetinib was 100 mg/12 h, with the main dose-limiting toxicities being hepatic cytolysis and rash.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Tom B. Davidson, Alexander Lee, Melody Hsu, Shaina Sedighim, Joey Orpilla, Janet Treger, Max Mastall, Saskia Roesch, Carmen Rapp, Mildred Galvez, Aaron Mochizuki, Joseph Antonios, Alejandro Garcia, Nikesh Kotecha, Nicholas Bayless, David Nathanson, Anthony Wang, Richard Everson, William H. Yong, Timothy F. Cloughesy, Linda M. Liau, Christel Herold-Mende, Robert M. Prins
CLINICAL CANCER RESEARCH
(2019)
Review
Oncology
Norbert Galldiks, Karl-Josef Langen, Nathalie L. Albert, Marc Chamberlain, Riccardo Soffietti, Michelle M. Kim, Ian Law, Emilie Le Rhun, Susan Chang, Julian Schwarting, Stephanie E. Combs, Matthias Preusser, Peter Forsyth, Whitney Pope, Michael Weller, Joerg C. Tonn
Article
Oncology
Jingwen Yao, Caleb Hock Pang Tan, Jacob Schlossman, Ararat Chakhoyan, Catalina Raymond, Whitney B. Pope, Noriko Salamon, Albert Lai, Matthew Ji, Phioanh L. Nghiemphu, Linda M. Liau, Timothy F. Cloughesy, Benjamin M. Ellingson
JOURNAL OF NEURO-ONCOLOGY
(2019)
Article
Multidisciplinary Sciences
Ararat Chakhoyan, Jingwen Yao, Kevin Leu, Whitney B. Pope, Noriko Salamon, William Yong, Albert Lai, Phioanh L. Nghiemphu, Richard G. Everson, Robert M. Prins, Linda M. Liau, David A. Nathanson, Timothy F. Cloughesy, Benjamin M. Ellingson
SCIENTIFIC REPORTS
(2019)
Article
Clinical Neurology
Y. -L. Wang, J. Yao, A. Chakhoyan, C. Raymond, N. Salamon, L. M. Liau, P. L. Nghiemphu, A. Lai, W. B. Pope, N. Nguyen, M. Ji, T. F. Cloughesy, B. M. Ellingson
AMERICAN JOURNAL OF NEURORADIOLOGY
(2019)
Review
Oncology
David Schiff, Martin Van den Bent, Michael A. Vogelbaum, Wolfgang Wick, C. Ryan Miller, Martin Taphoorn, Whitney Pope, Paul D. Brown, Michael Platten, Rakesh Jalali, Terri Armstrong, Patrick Y. Wen
Article
Oncology
Jingwen Yao, Ararat Chakhoyan, David A. Nathanson, William H. Yong, Noriko Salamon, Catalina Raymond, Sergey Mareninov, Albert Lai, Phioanh L. Nghiemphu, Robert M. Prins, Whitney B. Pope, Richard G. Everson, Linda M. Liau, Timothy F. Cloughesy, Benjamin M. Ellingson
Article
Oncology
Andrew McKinney, Olle R. Lindberg, Jane R. Engler, Katharine Y. Chen, Anupam Kumar, Henry Gong, Kan V. Lu, Erin F. Simonds, Timothy F. Cloughesy, Linda M. Liau, Michael Prados, Andrew W. Bollen, Mitchel S. Berger, Joseph T. C. Shieh, C. David James, Theodore P. Nicolaides, William H. Yong, Albert Lai, Monika E. Hegi, William A. Weiss, Joanna J. Phillips
MOLECULAR CANCER THERAPEUTICS
(2019)
Letter
Clinical Neurology
Mary Jane Lim-Fat, Wenya Linda Bi, Janet Lo, Eudocia Quant Lee, Manmeet S. Ahluwalia, Tracy T. Batchelor, Susan M. Chang, E. Antonio Chiocca, Ugonma Chukwueke, Timothy F. Cloughesy, Howard Colman, Lisa M. Deangelis, Evanthia Galanis, Mark R. Gilbert, John F. De Groot, Andrew B. Lassman, Linda M. Liau, Warren Mason, J. Ricardo McFaline-Figueroa, Minesh P. Mehta, Ingo K. Mellinghoff, L. Burt Nabors, Lakshmi Nayak, David A. Reardon, Patrick Y. Wen
Article
Biology
Xuchen Hu, Ken Matsumoto, Rachel S. Jung, Thomas A. Weston, Patrick J. Heizer, Cuiwen He, Norma P. Sandoval, Christopher M. Allan, Yiping Tu, Harry V. Vinters, Linda M. Liau, Rochelle M. Ellison, Jazmin E. Morales, Lynn J. Baufeld, Nicholas A. Bayley, Liqun He, Christer Betsholtz, Anne P. Beigneux, David A. Nathanson, Holger Gerhardt, Stephen G. Young, Loren G. Fong, Haibo Jian
Article
Neurosciences
M. A. Basso, S. Frey, K. A. Guerriero, B. Jarraya, S. Kastner, K. W. Koyano, D. A. Leopold, K. Murphy, C. Poirier, W. Pope, A. C. Silva, G. Tansey, L. Uhrig
Summary: Over the past decades, non-invasive imaging methods, particularly MRI, have become increasingly popular in neuroscience for studying brain structure and function. The use of MRI has not only improved surgical procedures and implants, but also enhanced diagnosis and monitoring for brain disease. Collaborating experts aim to guide researchers and veterinarians in using this imaging technology to improve the well-being and experimental outcomes for laboratory animals.
Review
Clinical Neurology
Timothy J. Brown, Daniela A. Bota, Martin J. van den Bent, Paul D. Brown, Elizabeth Maher, Dawit Aregawi, Linda M. Liau, Jan C. Buckner, Michael Weller, Mitchel S. Berger, Michael Glantz
NEURO-ONCOLOGY PRACTICE
(2019)